DarioHealth vs Spectral AI
DRIO and MDAI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DRIO and MDAI compare
Spectral AI is the larger company, worth 2.6 times as much as DarioHealth ($41.8M against $16.2M).
DarioHealth grew revenue faster over the last twelve months (−13.9% versus −44.1% for Spectral AI).
Spectral AI keeps more of each dollar of sales as profit, with a net margin of −65.5% compared with −160% at DarioHealth.
DarioHealth scores higher on the StockData Score (8 against 0 for Spectral AI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DRIO | MDAI |
|---|---|---|
| Size and price | ||
| Market cap | $16.2M | $41.8M |
| Share price | $1.65 | $1.30 |
| Change, 1 year | −86.4% | −18.8% |
| Change, 5 years | −99.5% | −86.8% |
| Beta (5Y) | 1.09 | 0.49 |
| Employees | 160 | 65 |
| StockData Score | ||
| Total score | 8 (better) | 0 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 1.0× | – |
| P/S | 0.8× (better) | 2.7× |
| P/B | 0.2× | – |
| PEG | 0.02 | – |
| FCF yield | −146% | – |
| Fair value | $46.49 | – |
| Margin of safety | 96.5% | – |
| Growth | ||
| Revenue growth (TTM) | −13.9% (better) | −44.1% |
| Revenue growth, 5Y average | 24.2% | – |
| EPS growth, 5Y average | 20.3% | – |
| Profitability | ||
| Gross margin | 57.9% (better) | 42.9% |
| Operating margin | −143% | −77.2% (better) |
| Net margin | −160% | −65.5% (better) |
| FCF margin | −111% | – |
| Return on equity | −46.6% | – |
| Return on invested capital | −33.1% | – |
| Financial health | ||
| Debt / equity | 0.44 | – |
| Interest coverage | −6.8× (better) | −9.7× |
| Current ratio | 4.20 (better) | 0.90 |
| Altman Z-score | −6.09 | −5.12 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.0% | 21.4% |
| Held by insiders | 13.7% | 20.5% |
| Insider net buying, 12 months | $100K | – |
| Short interest, % of float | 1.4% | – |
Go deeper
- DRIO stock overview
- DRIO income statement
- DRIO valuation and score
- MDAI stock overview
- MDAI income statement
- MDAI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.